Cornelius Supply Chain Pledge
European raw materials distributor has invested heavily in developing stringent quality procedures
The European raw materials distribution company with more than 75 years of experience has invested heavily in developing stringent procedures to ensure the quality of the materials it supplies.
‘We insist on the highest standards of ourselves and our supply partners so that our customers can buy with confidence,’ explained David Brown, managing director of Cornelius.
‘We check all our suppliers and validate their quality and systems to ensure that the goods we supply to customers are fit for purpose. The consequences of getting something like this wrong are too devastating to individual consumers and companies involved, and we will never compromise on our high standards.’
Under the Cornelius Supply Chain Pledge, all suppliers represented by the Cornelius Group are selected according to stringent standards, have robust quality systems, are audited, and meet legal and ethical standards.
Although Cornelius has been accredited to ISO 9000 since 1992 and embraced SA8000 in 2002, the company says it has always rejected the 'box ticking' approach and striven to use Quality Management Systems to add value both to its customers and principals. The introduction of the Cornelius Supply Chain Pledge demonstrates the company’s commitment to being the quality leader in the European chemical distribution field.
More information is available at: www.cornelius.co.uk/supply_chain_pledge
You may also like
Trending Articles
You may also like
Regulatory
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory
Overcoming CMC challenges in cell and gene therapy: part I
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs